* New executive appointment made ahead of pivotal study results, potential

    regulatory approval and subsequent commercialization of investigational
    COMP360 psilocybin treatment
  * Latest of several key executive team hires, rounding out team to take
    Compass through phase 3 and beyond

LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS)
("Compass"), a biotechnology company dedicated to accelerating access to
evidence-based innovation in mental health, today announced the appointment of
Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be
based in the company's New York City office.
Lori brings multifaceted experience in global pharmaceuticals and joins from
Axsome Therapeutics, where she spent nearly five years as a member of the
executive team serving as head of commercial and business development and most
recently as head of product strategy. She played an integral role in bringing
the company from clinical-stage to commercial-stage and was responsible for
formulating commercial launch strategy and scaling the commercial organization.
Over her career, Lori has launched multiple CNS-focused assets, at Axsome and at
Amgen, where she spent nearly a decade in several global brand roles, including
neuroscience and oncology/hematology, as well as roles in commercial strategy
and operations, corporate strategy and business development.
Lori's appointment follows that of Teri Loxam as Chief Financial Officer in
March 2024 and Dr. Michael Gold as Chief Research & Development Officer in May
2024. All three executive team members bring decades of successful strategic
leadership and highly relevant experience in drug development.
"With Lori's appointment, and with Teri and Mike joining the company earlier
this year, Compass Pathways now has in place an experienced executive team to
lead us through our phase 3 program in treatment-resistant depression and
prepare for a commercial launch should we receive regulatory approval for
COMP360," said Kabir Nath, CEO of Compass Pathways. "Lori's success in scaling
commercial organizations across global functions will build on the work we have
already begun to inform how to deliver COMP360 to patients and ensure broad and
equitable access. I am delighted to welcome Lori to our leadership team, united
by our mission to bring better options to people who urgently need them."
"I'm thrilled to be joining the Compass Pathways team at such an exciting and
pivotal time for the company and the broader field of mental health," said Lori
Englebert. "I feel a deep connection to the mission, and I am passionate about
helping bring transformative new therapies to the many patients who need better
therapeutic options. I am excited by the challenge of bringing a potentially
paradigm-shifting new treatment to patients and I am delighted that I will be
working alongside such an experienced team of leaders."
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment- resistant depression (TRD). We have commenced a phase 3 clinical program of COMP
360 psilocybin treatment in TRD, the largest randomised, controlled, double- blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (pÂ